Aileron Therapeutics, based in Cambridge, Massachusetts, is a biopharmaceutical company founded in 2005 to develop and advance a revolutionary class of drugs called Stapled Peptides. Aileron’s innovative and elegant peptide stabilization technology represents a breakthrough approach for modulating intracellular protein-protein interactions, critical control points for nearly all functions of a cell. The ability to target and regulate these control points affords the unique opportunity to exploit potentially thousands of well-characterized, yet currently "undruggable" cellular targets with applications in all human diseases.

Aileron’s proprietary technology locks peptides into their biologically active shape, mimicking the structures found in nature, and ultimately endows the peptide with unique and beneficial drug-like properties, including efficient cell penetration, high affinity binding to large target protein surfaces and excellent stability within the body.

Contact us to learn about sponsorship opportunities

About ProteinScience.com

 Company Archive

Companies                                                       

The revolution in genomics and proteomics spawned by the human genome project is providing a steady stream of protein therapeutic candidates. Many of these proteins require enhancements in their pharmacokinetic properties in order to be clinically effective because of inherent limitations of proteins as drugs.  Advanced Proteome Therapeutics has initiated a program that is broadly applicable to proteins. It builds on a technology platform developed over twenty years of targeting proteins for site-selective modification and addresses issues which limit therapeutic utilization of promising proteins.

The Company’s laboratories are located at the BioSquare Innovation and Discovery Center on the campus of the Boston University School of Medicine. Its scientists are engaged in research and development applying leading edge chemical and biochemical methodologies to commercially viable proteins. The technology is applicable to the generation of a variety of protein products including protein therapeutics, protein diagnostics and high value reagents for research.

Label-free interaction analysis is of increasing importance for scientists in the academic, pharmaceutical, biotechnology and diagnostic markets. Setting the performance benchmark, Biacore systems generate unique data on the interactions between proteins and other molecules, including small molecule drug candidates. During research, development and manufacture, these data give insights into protein functionality, elucidate disease mechanisms and play a key role in the critical decisions needed for efficient development and production of therapeutics.

Biacore systems are used in areas such as pharmaceutical drug discovery, antibody characterization, proteomics, immunogenicity, biotherapeutic development and manufacture, and many life science research applications. A range of systems meet specific application needs. Customers include leading research centers, all of the leading global pharmaceutical companies, and many biotechnology companies.

In the food analysis market, a system and ready-to-use kits provide key manufacturers with the ability to determine quality and safety in areas such as quantification of vitamin content and screening for veterinary drug residues.

Proteome Sciences is a life sciences company delivering content for personalised medicine through three areas:

• Services
• Biomarkers
• Reagents

Proteome Sciences, a global leader in applied proteomics, uses high sensitivity proprietary technologies to detect biomarkers (differentially expressed proteins in diseases) and to develop rapid assays for testing. The biomarkers discovered in body fluids or tissues are validated, developed and commercialised as diagnostic, prognostic or therapeutic products through strategic alliances and out-licensing.

PS Biomarker Services™ – A modular biomarker outsourcing solution to the pharmaceutical, biotechnology and diagnostics industries

Separate modules for discovery, validation and routine measurement of biomarkers are based around proprietary isobaric and isotopic Tandem Mass Tags® (TMT®) and both gel-based and gel-free separation technologies linked to state-of-the-art mass spectrometry. This significantly increases the speed, robustness and precision of biomarker discovery/quantification and facilitates the rapid transition to multiplex biomarker assays for routine application.

Biomarkers – A broad selection of proprietary protein biomarkers across a range of key human diseases

Proteome Sciences has established a comprehensive intellectual property portfolio covering markers in CNS disorders (Alzheimer’s, stroke, traumatic brain injury, TSE’s & pain), Oncology (lung, breast, esophageal, colorectal cancers & neuroblastoma) and organ transplant rejection (renal, cardiac).

Reagents – Proteome Sciences’ patented isobaric mass tag technology

Proteome Sciences has developed a range of novel isobaric and isotopic reagents under the Tandem Mass Tag® brand which are licensed and distributed worldwide by Thermo Scientific. TMT® works like a car tracker system to uniquely tag proteins and peptides, radically reducing the variability of biomarker discovery and speeding up the transition to biomarker validation. Proteome Sciences controls the global isobaric mass tag space through issued US and European TMT® patents.

Proteome Sciences has state-of-the-art research facilities in London, UK and ISO 9001:2008 accredited facilities in Frankfurt, Germany. These are complemented through a range of collaborations with leading academic research establishments worldwide.

All aspects of biomarker services, custom tagging, assay development and proteomics workflows can be outsourced from PS Biomarker Services.

NextGen Group PLC (LSE:NGG) is a provider of protein biomarker services, biomarkerexpress™, for pharmaceutical and biotech companies globally, operating as NextGen Sciences.

NextGen Sciences' range of services, which include biomarker discovery, assay development and a testing laboratory, are employed by customers as a key part of the drug and diagnostic development process. NextGen uses advanced and proprietary techniques to develop accurate, precise and robust biomarker assays, which are used to test pre-clinical and clinical samples for drug efficacy and safety, and for the development of personalized treatment for patients.

As well as biomarker services, NextGen Sciences has a range of capabilities to offer clients, including protein identification, characterization, quantitation and proteome mapping, and an enviable record for providing high-quality fast results.

NextGen Sciences' management team has a track record of progressing technology solutions and delivering first-class services to market. The company has worked with 16 of the top 20 pharmaceutical companies resulting in several Master Service Agreements being placed.

NextGen Sciences continues to invest in cutting-edge technologies and form strategic alliances to offer the best quality and most comprehensive protein biomarker services to its pharmaceutical and biotech customers.

Tyrian Diagnostics’ business is focused on the commercialisation of our intellectual property for the development of novel, diagnostic tests using our proprietary biomarkers and point-of-need test platform DiagnostIQ^TM.

Our capability is in clinical and agricultural applications, where there are large global markets and an unmet need for new or improved diagnostic reagents and tests, examples of which include:

• Wheat quality test, our first DiagnostIQ™ product developed with Bayer CropScience for the agricultural market.
• Tests for active tuberculosis, using our proprietary TB biomarkers.
• Development of sputum-based diagnostics for respiratory disease.

Tyrian Diagnostics has expertise in protein biomarker discovery and validation of these biomarkers as diagnostic reagents. We have developed proprietary methods for separating proteins of potential interest from complex clinical samples; and for enriching the concentration of low abundant or rare proteins for detection in diagnostic systems. Promising biomarkers are validated through Tyrian Diagnostics’ technology pipeline for potential application as diagnostic and prognostic tests, for monitoring disease progression and the effectiveness of drug treatments, or as surrogate markers in clinical trials.

We commercialise our products through partnerships with well established marketing and distribution companies. It is our aim to work closely with our partners throughout the commercialisation process in order to maximize the profitability of our products.

caprotec bioanalytics GmbH has developed a ground-breaking, proprietary technology to reduce the complexity of protein mixtures and samples in a targeted and directed manner.

caprotec's Capture Compound Mass Spectrometry (CCMS) Technology is based on multifunctional small molecules (Capture Compounds™) that are used to target, capture, and isolate proteins based on their functionality. For many applications, CCMS is clearly superior to shotgun approaches - thus addressing an unmet need in the proteomics community.

The technology is complementary to the most frequently used analytical tools in proteomics research, gel electrophoresis and affinity chromatography. caprotec is commercializing the CCMS technology as kits for research applications and in the form of collaborations for drug development. The focus in collaborative projects is on mechanisms of drug action and avoidance of toxicological effects of small molecule drugs. caprotec, founded by scientist and entrepreneur Prof. Dr. Hubert Koester, received initial financing in 2007 and moved into the headquarters in Berlin Adlershof in January 2008. The Adlershof facilities include office, laboratory and manufacturing space.

Waters is a leading resource for the delivery of tailored analytical solutions to meet the demands of leading proteomics and biomarker discovery research laboratories. Building on more than 30 years of experience, our advanced mass spectrometry systems maximize efficiency and provide unique tools for protein discovery, characterization, quantification, and validation.

Cellzome is a privately-owned drug discovery and development company, and a leader in the use of chemical proteomics technologies to identify a new generation of drug candidates for the treatment of inflammatory diseases.

Our pipeline of small-molecule therapeutics is driven by Kinobeads™, a proprietary technology for screening and profiling kinases in their physiological context. We have developed a new technology, called Episphere™ to address epigenetic targets in disease-specific protein complexes. Our goal is to identify oral therapeutics for inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. The overall market for autoimmune diseases is forecast to grow at 6.5% per annum to $25.6bn by 2016 [source: Datamonitor].

The management team has strong scientific and commercial credentials, and is backed by some of the biotech industry's most experienced investors. Cellzome is intent on developing both organically and through merger or acquisition, whilst maintaining its values of transparency, commitment and mutual respect.

Cellzome has two significant collaborations with GSK. Our holding company is domiciled in the US and we employ about 90 people at our two laboratories in Cambridge, UK and Heidelberg, Germany.

Nonlinear Dynamics develops proteomics analysis software that is different, ground-breaking and above all designed to help you generate reliable conclusions that are reproducible across-labs. Our new way of thinking has been applied to LC-MS, MALDI and 2D data analysis so you can make a real difference using a combination of the right techniques, your expertise and our Progenesis software.

Nonlinear Dynamics are one of the Founders of Fixing Proteomics and helping to spread the word so proteomics can regain the recognition it deserves. Being part of the campaign has totally changed Nonlinear's approach to proteomics analysis. If you've ever worried about issues like "have I run enough biological replicates through my mass spec?" or "how reliable and reproducible are my proteomics experiments?" then visit www.fixingproteomics.org. Here you'll find simple analogies that help anyone understand the challenges of running proteomics experiments and more importantly what you can do about it using 4-steps to Fixing Proteomics as well as practical advice on running high quality proteomics experiments.

The Proteome Factory AG is a modern biotech company specialized in proteomics, protein analysis, target validation and bioinformatics. The proteomic key technology platform significantly increases the chances to identify new drug targets in emerging disease and biomarkers of disease state. Additionally, the finding of biomarkers significantly enhances the opportunities for individual disease treatment. The Proteome Factory AG has developed an R&D key technology platform in life sciences and biotechnology. This technology platform is continuously optimized regarding efficiency, quality, and quantity. Combination of the core technologies proteomics, protein analysis, target validation and bioinformatics enables Proteome Factory AG to offer most rapid and reliable analyses of all kind of protein containing samples including body fluids, cells, tissues, and plants. The innovative proteomics platform ensures high sensitive and simultaneous analyses of a vast amount of proteins.

Reverse-Proteomics (pharmaco proteomics) facilitates investigation of molecular mode of action and toxicology of drugs and other compounds. Utilization and development of modern bioinformatic technologies are most relevant to the Proteome Factory AG. Integrated data mining and processing enhance quality and speed of interpretation.

Beside high resolution 2D electrophoresis (up to 60x30 cm) latest gel-free LC-MS based techniques are applied to proteome analysis. In combination with new prefractionation techniques low abundant proteins can be analyzed allowing the identification of new high potential targets and biomarkers (e.g. by depletion of albumin from serum samples or analysis of albumin-bound proteins). Furthermore combination of de novo peptide sequencing by state-of-the-art mass spectrometry, HPLC, N-terminal protein and peptide sequencing allows Proteome Factory a reliable identification of post translational modifications (e.g. phosphorylation) and characterization of proteins’ primary structure.

The Proteome Factory AG has filed several patents for proteomic techniques. Selective Peptide Exclusion Chromatography (SPEC) allows a significant reduction of sample complexity while its content of information is not affected. Metal coded tagging (MeCAT) is a novel class of labeling reagents allowing quantitative multiplex analyses of several complex protein samples at the same time. First time MeCAT allows absolute quantification of proteins and biomolecules at a very sensitive level and a linear dynamic detection range of up to 9 orders of magnitude. Thus MeCAT is much more powerful than alternative techniques like stable isotope tagging.

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. For more information on how we are making a difference please visit our website: www.lifetechnologies.com

Caprion’s leading and proprietary proteomics discovery technologies - CellCarta® - enable the discovery of novel targets for therapeutics development and the identification of novel protein biomarkers that can significantly reduce risk and enhance clinical development productivity and decision making in pharmaceutical research.

Caprion’s proteomics discovery platform - CellCarta® - is the leading means for profiling proteins in solid tissues and plasma. CellCarta® is a proprietary, state-of-the-art proteomics technology platform that serves as an engine for unparalleled disease target identification, predictive medicine and the creation of a proprietary therapeutic product pipeline. The power of Caprion’s technology has been successfully leveraged to secure multiple, platform-validating, revenue generating partnerships surrounding oncology therapeutic target identification and clinical biomarker discovery.

About ProteinScience.com